<DOC>
	<DOCNO>NCT02618603</DOCNO>
	<brief_summary>Shoulder pain stroke common , cause significant morbidity disease . Subacromial subdeltoid ( SASD ) bursitis common cause pain disability shoulder joint stroke patient . Traditional therapeutic approach shoulder pain therapy include pharmacotherapy , injection therapy , physical therapy , behavioural modification . Unfortunately , therapy method may effective many patient long term benefit treatment transient , outcome may also incomplete non-existent . Botulinum toxin A ( BoNT-A ) neurotoxin inhibit acetylcholine neuromuscular junction also neurotransmitter glutamate , substance P calcitonin gene related peptide , indicate pain transmission . Despite therapeutic benefit BTX alleviate painful muscle spasm , efficacy SASD bursitis condition less clear . So perform study examine efficacy ultrasound guide SASD injection BoNT-A reduce refractory shoulder pain stroke .</brief_summary>
	<brief_title>Botulinum Toxin A Shoulder Pain After Stroke</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Shoulder Pain</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>1 . Stroke patient pain around shoulder lateral deltoid area deteriorate active passive overhead activity ; 2 . Neer and/or Hawkins test ( + ) ; 3 . NRS &gt; 5 rest ; 4 . Symptoms last least 2 month unresponsive analgesic medication physical therapy 1 month . 5 . Subjects voluntarily sign informed consent . 6 . Age 18 80 year old . 1 . Received earlier subacromial injection corticosteroid botulinuim toxin last 6 month ; 2 . Shoulder fracture , glenohumeral osteoarthritis , bone tumor osteonecrosis plain radiograph . 3 . Known allergy sensitivity study medication component . 4 . Infection dermatological condition injection site . 5 . Any medical condition may put subject increase risk exposure , include diagnose myasthenia gravis , EatonLambert syndrome , amyotrophic lateral sclerosis , disorder might interfere neuromuscular function . 6 . QTc criterion : QTc ≥ 450 millisecond ( msec ) or≥480msec subject Bundle Branch Blockvalues base either single electrocardiogram ( ECG ) value triplicate ECG average QTc value obtain brief recording period 7 . Liver function test : aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≥2xULN ; alkaline phosphatase bilirubin ＞1.5xULN ( isolated bilirubin &gt; 1.5ULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . 8 . Concurrent use aminoglycoside antibiotic agent might interfere neuromuscular function . 9 . Patients severe cognitive impairment neurological disease affect implementation evaluation test , drugdependent patient . 10 . Presence clinically unstable severe cardiovascular , renal respiratory disease 11 . Researchers believe factor unfit participate study patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Stroke</keyword>
	<keyword>Should pain</keyword>
	<keyword>Botulinum Toxin</keyword>
</DOC>